In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study

Andrew Walkty; James A Karlowsky; Melanie R Baxter; Heather J Adam; George G Zhanel

doi:10.1128/AAC.02068-18

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study

Antimicrob Agents Chemother. 2018 Dec 21;63(1):e02068-18. doi: 10.1128/AAC.02068-18. Print 2019 Jan.

Authors

Andrew Walkty^{1

2}, James A Karlowsky^{3

2}, Melanie R Baxter³, Heather J Adam^{3

2}, George G Zhanel³

Affiliations

¹ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada AWalkty@sharedhealthmb.ca.
² Shared Health, Winnipeg, Manitoba, Canada.
³ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Abstract

The Clinical and Laboratory Standards Institute (CLSI) broth microdilution method was used to evaluate the in vitro activities of plazomicin and comparator antimicrobial agents against 7,712 Gram-negative and 4,481 Gram-positive bacterial pathogens obtained from 2013 to 2017 from patients in Canadian hospitals as part of the CANWARD Surveillance Study. Plazomicin demonstrated potent in vitro activity against Enterobacteriaceae (MIC₉₀ ≤ 1 µg/ml for all species tested except Proteus mirabilis and Morganella morganii), including aminoglycoside-nonsusceptible, extended-spectrum β-lactamase (ESBL)-positive, and multidrug-resistant (MDR) isolates. Plazomicin was equally active against methicillin-susceptible and methicillin-resistant isolates of Staphylococcus aureus.

Keywords: Gram-negative bacteria; Gram-positive bacteria; aminoglycosides; multidrug resistance; plazomicin.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Canada / epidemiology
Epidemiological Monitoring
Fluoroquinolones / pharmacology
Glycopeptides / pharmacology
Gram-Negative Bacteria / drug effects*
Gram-Negative Bacteria / growth & development
Gram-Negative Bacteria / isolation & purification
Gram-Negative Bacterial Infections / epidemiology
Gram-Negative Bacterial Infections / microbiology
Gram-Positive Bacteria / drug effects*
Gram-Positive Bacteria / growth & development
Gram-Positive Bacteria / isolation & purification
Gram-Positive Bacterial Infections / epidemiology
Gram-Positive Bacterial Infections / microbiology
Hospitals
Humans
Macrolides / pharmacology
Microbial Sensitivity Tests
Sisomicin / analogs & derivatives*
Sisomicin / pharmacology
beta-Lactams / pharmacology

Substances

Anti-Bacterial Agents
Fluoroquinolones
Glycopeptides
Macrolides
beta-Lactams
plazomicin
Sisomicin